A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negative Breast Cancer Proceeding to an Open Label Randomized Phase II Trial Comparing Gemcitabine/Cisplatin With or Without RAD001.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Everolimus (Primary) ; Cisplatin; Gemcitabine
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 28 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 May 2015 Planned End Date changed from 1 Jul 2018 to 1 Jul 2017, as reported by ClinicalTrials.gov.